Targeting the prostate-specific membrane antigen for prostate cancer therapy.
Immunotherapy
; 1(3): 471-81, 2009 May.
Article
em En
| MEDLINE
| ID: mdl-20635963
ABSTRACT
Prostate cancer remains a leading cause of death for men in Western civilization. Despite the effectiveness of surgical prostatectomy, radiotherapy and hormonal therapy, a significant proportion of patients progress to advanced metastatic disease for which there are currently no curative treatment options. Therefore, new therapeutic approaches need to be considered. The prostate-specific membrane antigen is a cell-surface glycoprotein that is highly and specifically expressed on prostate epithelial cells and strongly upregulated in prostate cancer at all stages. These characteristics make it an attractive target for antibody-based imaging and therapies and the first anti-prostate-specific membrane antigen agents have already entered clinical trials. The proposed strategies include targeted toxins and radiotherapeutics as well as immunotherapeutic agents and vaccines.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Carcinoma
/
Glutamato Carboxipeptidase II
/
Antígenos de Neoplasias
/
Antígenos de Superfície
Idioma:
En
Ano de publicação:
2009
Tipo de documento:
Article